Effectiveness of Probiotic K10 in Managing Health Outcomes in Parkinson and Alzheimer Disease (Probiótic)

Inclusion Criteria: Eligibility criteria for individuals with Parkinson's. Ages eligible to participate in the study: 18 years or older Accept healthy volunteers: No. Gender Eligibility for Study: All genders Inclusion criteria: Presence of all 3 cardinal features of Parkinson's disease (tooth tremor, bradykinesia, and rigidity). Clinical signs must be asymmetrical. Diagnosis of Parkinson's disease within 5 years of the Screening Visit. Age 18 years or older. Women must not be of childbearing potential or must use an approved form of contraception during the trial period. Eligibility Criteria for Individuals with Alzheimer's. Eligible ages to participate in the study: 60 -85 years Accept healthy volunteers: No. Gender Eligibility for Study: All genders Inclusion criteria: Men or women between the ages of 60 and 85 Diagnosis of probable Alzheimer's disease Portuguese-speaking, English-speaking; Spanish-speaking if the individual site allows Study partner or caregiver to ensure compliance Mini-Mental State Exam score at screening visit greater than 14 Stable medical condition for 3 months prior to screening, with no significant abnormal liver, kidney, or blood studies. Able to take oral medications Modified Hachinski Ischemic Index less than or equal to 4 CT or MRI from the onset of memory impairment, demonstrating the absence of a clinically significant focal lesion Physically acceptable for this study, as confirmed by medical history, physical examination, neurological examination, and clinical testing Exclusion Criteria: Parkinson's Exclusion Criteria: Parkinsonism due to drugs including neuroleptics, alpha-methyldopa, reserpine, metoclopramide, valproic acid. Use of antioxidants (such as selegiline, rasagiline, vitamins E and C), additional supplemental vitamins or minerals, regular use of neuroleptics, chloramphenicol, valproic acid, warfarin. Other parkinsonian disorders. Modified Hoehn and Yahr score of 3 or more on Screening Visit or Baseline Visit. UPDRS tremor score of 3 or greater at Screening Visit or Baseline Visit. History of symptomatic stroke. Sufficient deficiency to require changes in dopaminergic medication treatment during follow-up compared to baseline treatment schedule. Other severe and uncompensated illnesses, including severe psychiatric illnesses. Patients with active cardiovascular, restrictive peripheral vascular, or cerebrovascular disease in the past year. Unstable dose of active CNS therapies. Use of appetite suppressants within 60 days of the Baseline Visit. History of active epilepsy within the past 5 years. Participation in other drug studies or use of other investigational drugs within 30 days prior to the Screening Visit. History of electroconvulsive therapy. History of any brain surgery for Parkinson's disease. History of structural brain disease, such as previous trauma causing damage detected on a CT scan or MRI, hydrocephalus, or previous brain neoplasms. Alzheimer's Exclusion Criteria: Significant neurological disease such as Parkinson's disease, stroke, brain tumor, multiple sclerosis, or seizure disorder Major depression treated in the past 12 months, major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse History of invasive cancer within the past two years (excluding non-melanoma skin cancer) Use of any investigational agents within 30 days prior to screening Major surgery within 8 weeks prior to the Baseline Visit Uncontrolled cardiac conditions or severe unstable medical illnesses Antiretroviral therapy for human immunodeficiency virus (HIV) Conditions that will contribute to oxidative stress: current cigarette or cigar smokers (within past month), diabetics on insulin or poorly controlled on oral hypoglycemics Blindness, deafness, language difficulties or any other disability which may prevent the participant from participating or cooperating in the protocol.